Amplo Biotechnology is to develop multiple, potentially curative, Adeno-Associated Viral (AAV) therapies for the neuromuscular junction.
Amplo Biotechnology has raised $2.9M in total funding. The most recent round was Grant. The last funding was announced in January 2025.
Amplo Biotechnology's investors include Casdin Capital, National Institutes of Health, California Institute for Regenerative Medicine, SeedFolio, NIAMS.
Amplo Biotechnology is headquartered in La Jolla, United States.
Amplo Biotechnology is to develop multiple, potentially curative, Adeno-Associated Viral (AAV) therapies for the neuromuscular junction.
Amplo Biotechnology is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Amplo Biotechnology — Funding & Investors." VCBacked, January 30, 2025, https://www.vcbacked.co/company/amplo-biotechnology. Accessed July 19, 2026.
VCBacked. (2025). Amplo Biotechnology — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/amplo-biotechnology
{{cite web |title=Amplo Biotechnology — Funding & Investors |url=https://www.vcbacked.co/company/amplo-biotechnology |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated